series-a
Stage
2
Investors
About
March Biosciences is a clinical-stage cell therapy company developing CAR-T cell therapies targeting hematological cancers, with a lead asset MB-105 focused on treating relapsed/refractory T-cell lymphoma by targeting the CD5 antigen.
Explore March Biosciences's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.